// App-Quantinova.ai

: A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Researchers

Presenter

  • Carmelo Carlo-Stella

Principal Investigators

  • Anna Sureda

  • Luís Francisco Araújo

  • Olivier Casasnovas

  • Cecilia Carpio

  • Su-Peng Yeh

  • Krimo Bouabdallah

  • Guillaume Cartron

  • Won Seog Kim

  • Raul Cordoba

  • Youngil Koh

  • Alessandro Re

  • Daniela Alves

  • Martine E.D Chamuleau

  • Steven Le Gouill

  • Armando Lopez-Guillermo

  • Maria Ilidia Moreira

  • Marjolein W.M. Van der Poel

  • Giovanni Abbadessa

  • Robin Meng

  • Ran Ji

  • Lucie Lepine

  • Rao Saleem

  • Vincent Ribrag

Medical Centers

  • Fundacion Jimenez Diaz University Hospital, Madrid, Spain

  • Département d'Hématologie et Département des Essais Précoces (DITEP), Institut Gustave Roussy, Villejuif, France

  • Humanitas Cancer Center, Rozzano, Italy

  • Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Universitário de Coimbra, Coimbra, Portugal

  • Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France

  • Department of Onco-Hematology, Portuguese Institute of Oncology of Porto, Porto, Portugal

  • Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Hospital Universitario Vall d'Hebrón, Barcelona, Spain

  • Institut Català d'Oncologia - Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain

  • Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain

  • Hematology and Bone Marrow Transplant Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal

  • Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France

  • Hematology and Cellular Therapy Department, University Hospital of Bordeaux, Bordeaux, France

  • Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, Netherlands

  • Department of Hematology, Nantes University Hospital, Nantes, France

  • Department of Hematology, Maastricht University Medical Center, Maastricht, Netherlands

  • Hematology, ASST Spedali Civili di Brescia, Brescia, Italy

  • China Medical University Hospital, Taichung, Taiwan

  • Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South)

Locations

  • Spain

  • Italy

  • France

  • Portugal

  • Republic of South Korea

  • Netherlands

  • United States

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Cutaneous squamous cell carcinoma

  • Squamous cell carcinoma

  • Basal cell carcinoma

  • Solid malignancies

  • Lymphomas

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Epidermal growth factor receptor

  • Proto-oncogene tyrosine-protein kinase ROS

  • Programmed death-ligand 1

  • Apparent diffusion coefficient

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • carfilzomib Intravenous

  • Isatuximab

  • Sandolase

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved